The federal judge presiding over the Zoloft multidistrict litigation has granted Pfizer’s request to toss the MDL on the grounds that the plaintiffs couldn’t muster an expert to illustrate a link between the drug and birth defects.
On Tuesday, U.S. District Judge Cynthia Rufe of the Eastern District of Pennsylvania effectively ended the MDL—pending any appeals to the Third Circuit—which has been going on for over three years. According to Rufe’s order, the clerk was instructed to close all but 23 of the more than 300 remaining cases, which were against defendants other than Pfizer and co-defendant Wolters Kluwer Health.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]